GlobeNewswire: Cabaletta Bio Contains the last 10 of 103 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T15:12:02ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/21/2850085/0/en/Cabaletta-Bio-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=51609Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update2024-03-21T11:00:00Z<![CDATA[– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program –]]>https://www.globenewswire.com/news-release/2024/03/20/2849225/0/en/Cabaletta-Bio-Announces-FDA-Granted-Orphan-Drug-Designation-to-CABA-201-for-Treatment-of-Systemic-Sclerosis.html?f=22&fvtc=4&fvtv=51609Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis2024-03-20T11:00:00Z<![CDATA[PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, for the treatment of systemic sclerosis (SSc). CABA-201 is in development as a potential treatment for autoimmune diseases driven by B cells. The RESET™ (REstoring SElf-Tolerance) clinical trial program includes four Phase 1/2 trials advancing for the evaluation of CABA-201 across multiple autoimmune conditions, including the Phase 1/2 RESET-SSc™ trial.]]>https://www.globenewswire.com/news-release/2024/02/27/2835938/0/en/Cabaletta-Bio-to-Participate-in-Upcoming-Investor-Conferences-in-March.html?f=22&fvtc=4&fvtv=51609Cabaletta Bio to Participate in Upcoming Investor Conferences in March2024-02-27T13:00:00Z<![CDATA[PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in March:]]>https://www.globenewswire.com/news-release/2024/02/01/2822479/0/en/Cabaletta-Bio-Announces-FDA-Granted-Orphan-Drug-Designation-to-CABA-201-for-Treatment-of-Myositis.html?f=22&fvtc=4&fvtv=51609Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis2024-02-01T21:30:00Z<![CDATA[PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, for the treatment of idiopathic inflammatory myopathies (IIM, or myositis). CABA-201 is in development as a potential treatment for autoimmune diseases driven by B cells. Four RESET™ (REstoring SElf-Tolerance) Phase 1/2 trials are advancing for the evaluation of CABA-201 across multiple autoimmune conditions, including the Phase 1/2 RESET-Myositis™ trial.]]>https://www.globenewswire.com/news-release/2024/01/31/2821065/0/en/Cabaletta-Bio-to-Participate-in-the-Guggenheim-Healthcare-Talks-6th-Annual-Biotechnology-Conference.html?f=22&fvtc=4&fvtv=51609Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference2024-01-31T13:00:00Z<![CDATA[PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 10:00 a.m. ET in New York, NY.]]>https://www.globenewswire.com/news-release/2024/01/08/2805284/0/en/Cabaletta-Bio-Receives-Additional-FDA-Fast-Track-Designations-for-CABA-201-in-Dermatomyositis-and-Systemic-Sclerosis.html?f=22&fvtc=4&fvtv=51609Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis2024-01-08T12:00:00Z<![CDATA[– Second and third FDA Fast Track Designations for CABA-201, following the systemic lupus erythematosus (SLE) and lupus nephritis (LN) designation, providing the opportunity for expedited development and review of CABA-201 for the treatment of these autoimmune diseases –]]>https://www.globenewswire.com/news-release/2024/01/02/2802636/0/en/Cabaletta-Bio-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=51609Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference2024-01-02T13:00:00Z<![CDATA[PHILADELPHIA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT (8:15 p.m. ET) in San Francisco, CA.]]>https://www.globenewswire.com/news-release/2023/11/28/2787379/0/en/Cabaletta-Bio-to-Participate-in-the-6th-Annual-Evercore-ISI-HealthCONx-Conference.html?f=22&fvtc=4&fvtv=51609Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference2023-11-28T21:30:00Z<![CDATA[PHILADELPHIA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at 8:20 a.m. ET in Miami, FL.]]>https://www.globenewswire.com/news-release/2023/11/09/2777162/0/en/Cabaletta-Bio-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=51609Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update2023-11-09T12:00:00Z<![CDATA[– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clinical site actively recruiting patients –]]>https://www.globenewswire.com/news-release/2023/11/06/2773926/0/en/Cabaletta-Bio-Receives-FDA-Clearance-of-CABA-201-IND-Application-for-Treatment-of-Generalized-Myasthenia-Gravis.html?f=22&fvtc=4&fvtv=51609Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis2023-11-06T12:00:00Z<![CDATA[– First cleared CD19-CAR T IND application for generalized myasthenia gravis announced in the U.S. and fourth IND clearance for CABA-201 across a broad range of autoimmune diseases –]]>